Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
about
Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemiaHomoharringtonine: history, current research, and future direction.Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemiaEffect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.Screening of allergic components mediated by H(1)R in homoharringtonine injection through H(1)R/CMC-HPLC/MS.Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.Homoharringtonine: a new treatment option for myeloid leukemia.A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study.A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndromeHomoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approvalPharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumorsNew natural products in cancer chemotherapy.Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway.Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.Omacetaxine mepesuccinate for the treatment of leukemia.Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation.
P2860
Q33396739-6FB20B8E-49AD-43CD-959C-3E6BEDCC1BF2Q33721114-4105A84A-076F-4166-A175-5C6A9815C7CAQ34105271-9BB7E435-1546-44DC-B499-65C5ABE94815Q34154708-9DFC936B-F859-41B1-ACB1-A2594EF1F747Q34568840-7068C1CB-E493-465A-8E04-71067EF4C613Q34996869-1CBF0774-49C0-4B52-A5AC-9A3D8CD820F9Q35168519-BC1309C2-3383-4203-AB36-8E53BE1EE1F2Q35844693-F3CDAF91-0C2A-41F4-BA23-AA75AD925D6AQ35994823-C4537D32-F621-4DF6-B0B0-5E4F01D5AE1CQ36612188-5960A911-D734-4E50-B25B-C61B50A0FAE4Q37036452-0B068D26-A563-4019-80D9-2CE851963807Q37100798-B6944F09-F707-4D81-8FF8-4AF14A196ABAQ37179439-D23D0E51-F502-452A-8EA8-82CDA9740DBAQ37222797-5F5F3749-73C7-434C-AFEE-BE0BDE144C6CQ37608749-75EFD4D3-4D65-4EB6-833E-7B25A6DC2B70Q37729281-FDFF4E97-9826-4617-A5B5-403803470A64Q38187115-77455BA6-2270-40D6-B4B1-CE2A627B32EEQ38846325-D33EA848-C9DD-4AE0-9633-6D62987B0556Q40135344-44C48414-4A52-47F4-91BB-80D732685677Q43947310-86488955-0A20-40D4-99DB-E9AF718B919CQ44098559-67D87C0F-7D0D-468F-9C10-F09E42F1437AQ46298902-A0F29D24-334B-4287-B0D1-A6BD13C7BE11Q52892987-8FC80C45-8FDC-4398-9F2C-A5A2444A1376Q55079595-5B9B463B-B2CD-4D55-B81C-B82C28B7E146
P2860
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@ast
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@en
type
label
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@ast
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@en
prefLabel
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@ast
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@en
P2093
P1433
P1476
Phase II study of low-dose con ...... ry acute myelogenous leukemia.
@en
P2093
Freireich EJ
Kantarjian HM
Keating MJ
McCredie KB
Walters RS
P304
P356
10.1002/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V
P407
P577
1989-03-01T00:00:00Z